Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have liver metastases, lung metastases, or other advanced solid tumors.

Detailed Description
-----------------
OBJECTIVES: Determine the feasibility of fractionated stereotactic body radiosurgery in patients with advanced extracranial tumors. Assess the toxicities of this treatment regimen in these patients. Determine tumor response and cause of death in these patients treated with this regimen. OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for 5-10 days for a total of 3 treatments. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.

Official Title
-----------------
Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors

Conditions
-----------------
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Intervention / Treatment
-----------------
* Radiation: stereotactic radiosurgery


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed malignancy Extracranial recurrent or metastatic disease or primary tumor not predicted to be controlled with standard radiotherapy Incurable with any standard therapy No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or heart) Tumor visible by CT scan PATIENT CHARACTERISTICS: Age: Not specified Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2.0 times upper limit of normal (ULN) AST and ALT less than 5 times ULN Renal: Creatinine less than 2.0 mg/dL Pulmonary: FEV1 greater than 0.75 L Other: No unsuitable size or geometric proportion that would preclude stereotactic immobilization Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: At least 14 days since prior anticancer biologic therapy and recovered Chemotherapy: At least 14 days since prior anticancer chemotherapy and recovered Endocrine therapy: At least 14 days since prior anticancer endocrine therapy and recovered Radiotherapy: See Disease Characteristics At least 14 days since prior anticancer radiotherapy and recovered Surgery: Not specified
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: stereotactic radiosurgery|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
unspecified adult solid tumor, protocol specific, lung metastases, liver metastases